Clinical Trials are an integral part of our research for Primary Sclerosing Cholangitis (PSC). Currently, there are four clinical trials open for PSC patients at Mayo Clinic:
Ongoing Clinical Trials
Investigation of Vidofludimus Calcium for PSC. Open label study, 6 month treatment period. For more details please go to: ClinicalTrials.gov Identifier: NCT03722576
Investigation of Cilofexor (an FXR agonist) for PSC. Randomized, placebo-controlled study, 96 week treatment period. For more details please go to: ClinicalTrials.gov Identifier: NCT03890120
This phase II, randomized, placebo-controlled clinical trial is designed to examine the safety, tolerability and efficacy of daily dosing (over an 18-month period) with oral vancomycin, using a stepped-up dosing strategy with three increasing doses, on the clinical course, and the progression of PSC, and to compare the treated patients with those on placebo.
This translational study seeks to generate the first, multi-omics and comprehensive clinical data resource for PSC. The study aims to define the bigger-picture cellular networks and gene-environment interactions driving PSC by integrating several layers of -omics data. In so doing, we will identify molecular disease signatures, including environmental toxins, metabolism-related chemicals and gut bacteria, unique to PSC patients.
Clinical Trials and PSC
In the following video, Dr. John E. Eaton details the importance of clinical trials in PSC research.
In this video, Dr. Eaton describes the challenges in developing clinical trials for PSC research.